Ocugen (OCGN) Non-Current Deffered Revenue (2014 - 2019)
Ocugen's (OCGN) quarterly Non-Current Deffered Revenue came in at $10.0 million in Q2 2019, up 3054.57% YoY from $317000.0 in Q2 2018, and little changed on a QoQ basis from $10.0 million in Q1 2019.
Ocugen (OCGN) Non-Current Deffered Revenue (2014 - 2019) Analysis & Trends
Ocugen (OCGN) has 6 years of Non-Current Deffered Revenue data on file, last reported at $10.0 million in Q2 2019.
- Quarterly Non-Current Deffered Revenue rose 3054.57% year-over-year to $10.0 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $10.0 million (up 3054.57% YoY) and the FY2018 annual result came in at $3739.0, down 98.66% from the prior year.
- Non-Current Deffered Revenue held at $10.0 million in Q2 2019, from $10.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $10.0 million in Q1 2019 to a low of $3739.0 in Q4 2018.
- A 5-year average of $1.9 million and a median of $382500.0 in 2015 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue slumped 98.66% — and 2019, when it soared 3054.57%.
- Tracing OCGN's Non-Current Deffered Revenue over 5 years: stood at $451000.0 in 2015, then plunged by 30.16% to $315000.0 in 2016, then retreated by 11.11% to $280000.0 in 2017, then tumbled by 98.66% to $3739.0 in 2018, then surged by 267351.19% to $10.0 million in 2019.
- The last three Non-Current Deffered Revenue figures came in at $10.0 million (Q2 2019), $10.0 million (Q1 2019), and $3739.0 (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 10.00 Mn |
| Mar 31, 2019 | 10.00 Mn |
| Dec 31, 2018 | 3,739.00 |
| Sep 30, 2018 | 5.00 Mn |
| Jun 30, 2018 | 317,000.00 |
| Mar 31, 2018 | 5.00 Mn |
| Dec 31, 2017 | 280,000.00 |
| Sep 30, 2017 | 289,000.00 |
| Jun 30, 2017 | 298,000.00 |
| Mar 31, 2017 | 308,000.00 |
| Dec 31, 2016 | 315,000.00 |
| Sep 30, 2016 | 349,000.00 |
| Jun 30, 2016 | 384,000.00 |
| Mar 31, 2016 | 418,000.00 |
| Dec 31, 2015 | 451,000.00 |
| Sep 30, 2015 | 381,000.00 |
| Jun 30, 2015 | 413,000.00 |
| Mar 31, 2015 | 445,000.00 |
| Dec 31, 2014 | 379,000.00 |